Low-dose hormone therapy in the perimenopause

International Journal of Gynecology and Obstetrics

Volumn 98, Issue 2, 2007, Pages 138-142

  De Franciscis, P ^a   Cobellis, L ^a   Fornaro, F ^a   Sepe, E ^a   Torella, M ^a   Colacurci, N ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Bleeding pattern; Dydrogesterone; Hot flushes; Low dose hormone therapy; Perimenopause; Vasomotor symptom

Indexed keywords

CHOLESTEROL; DYDROGESTERONE; ESTRADIOL; FEMOSTON L; FIBRINOGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOATING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEADACHE; HOT FLUSH; HUMAN; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENSTRUAL IRREGULARITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 34447264747     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijgo.2007.04.008     Document Type: Article

References (25)

1. Soules M.R., Sherman S., Parrott E., Rebar R., Santoro N., Utian W., et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW) Park City, Utah, July, 2001. Menopause 8 (2001) 402-407
2. Harlow S.D., Cain K., Crawford S., Dennerstein L., Little R., Mitchell E.S., et al. Evaluation of four proposed bleeding criteria for the onset of late menopausal transition. J Clin Endocrinol Metab 91 9 (2006) 3432-3438
3. Oldenhave A., Jaszmann L.J., Haspels A.A., and Everaerd W.T. Impact of climacteric on well-being: a survey based on 5213 women 39 to 60 years. Am J Obstet Gynecol 168 (1993) 772-780
4. Fisher W.A., Sand M., Lewis W., and Boroditsky R. Canadian menopause study-I: understanding women's intentions to utilise hormone replacement therapy. Maturitas 37 1 (2000) 1-14
5. Casper R.F., Dodin S., Reid R.L., et al. The effect of 20 mg ethinyl oestradiol/1 mg norethindrone acetate (Minestrin), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women. Menopause 4 (1997) 139-147
6. Kaunitz A.M. Oral contraceptive use in perimenopause. Am J Obstet Gynecol 185 (2001) S32-S37
7. Liu J.H. Therapeutic effects of progestins, androgens, and tibolone for menopausal symptoms. Am J Med 118 12 Suppl 2 (2005) 88-92
8. von Holst T., Lang E., Winkler U., and keil D. Bleeding pattern in peri and postmenopausal women takimg a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone. Maturitas 43 4 (2002) 265-275
9. Shulman L.P., and Larari D. Low-dose transdermal estradiol for symptomatic perimenopause. Menopause 11 1 (2004) 34-39
10. McKinlay S.M. The normal menopause transition: an over view. Maturitas 23 2 (1996) 137-345
11. Davis A., Godwin A., Lippman J., et al. Triphasic norgestimate-ethinyl oestradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 96 (2000) 913-920
12. Hampton R.M., Short M., Bieber E., et al. Comparison of a novel norgestimate/ethinyl oestradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception 63 6 (2001) 289-295
13. Liu S.L., and Lebrun C.M. Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review. Br J Sports Med 40 1 (2006) 11-24
14. Gambacciani M., Monteleone P., Ciaponi M., Sacco A., and Genazzani A.R. Effects of oral contraceptives on bone mineral density. Treat Endocrinol 3 3 (2004) 191-196
15. Moen M.H., Kahn H., Bjerve K.S., and Halvorsen T.B. Menometrorrhagia in the perimenopause is associated with increased serum estradiol. Maturitas 47 2 (2004) 151-155
16. Hampton N.R., Rees M.C., Lowe D.G., Rauramo I., Barlow D., and Guillebaud. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 20 9 (2005) 2653-2660
17. Mc Kinlay S.M., Brambilla D.J., and Posner. The normal menopause transition. Maturitas 14 2 (1992) 103-115
18. The North American Menopause Society. Recommendations for estrogen and progestogen use in peri and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause 11 6 (2004) 589-600
19. Skouby S.O., Al-Azzawi F., Barlow D., Calaf-Alsina Erdogan Ertungealp J., Gompel A., Graziottin A., et al. European Menopause and Andropause Society. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 51 1 (2005) 8-14
20. Lacey R.W., Howson G., and Samson G.A. Safety of progestins: effects of dydrogesterone on blood lipids. Br J Clin Pract 24 (1983) 2-10
21. Repina M.A., Korzo T.M., and Zinina T.A. Effect of hormone replacement therapy with femoston on hemostasis in peri- and postmenopausal women. Med Sci Monit 8 9 (2002) 78-84
22. Mijatovic V., van der Mooren M.J., Stehouwer C.D., Netelenbos J.C., and Kenemans P. Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection. Gynecol Endocrinol 13 (1999) 130-144
23. Vihtamaki T., Savilahti R., and Tuimala R. Why do postmenopausal women discontinue hormone replacement therapy?. Maturitas 33 (1999) 99-105
24. Utian W.H., Gass M.L., and Pickar J.H. Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women. Menopause 11 3 (2004) 306-314
25. Gambacciani M., and Genazzani A.R. Hormone replacement therapy: the benefits in tailoring the regimen and dose. Maturitas 40 (2001) 195-201